Determined maximum tolerated dose (MTD) in Phase 1 monotherapy study of NUV-868; Phase 1b studies of NUV-868 in combination with olaparib or enzalutamide remain ongoing
Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) application for NUV-1511, the first clinical candidate from our novel drug-drug conjugate (DDC) platform
Strong balance sheet with cash, cash equivalents and marketable securities of $611.2 million as of December 31, 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.